Thermo Fisher Scientific filings document operating results, material agreements, governance matters and capital-structure disclosures for a global supplier of scientific instruments, laboratory products, diagnostics, life science tools and pharmaceutical services. Recent Form 8-K reports include quarterly and annual results, acquisition-related events and definitive agreements.
The company’s proxy materials cover shareholder voting and board-governance matters. Its securities disclosures identify common stock and multiple NYSE-listed senior note classes, while Form 25 filings document removal from listing and registration for specific senior notes. The filing record also includes risk-factor and corporate disclosure categories tied to Thermo Fisher’s operating businesses and financing structure.
Keith R. Alexandra reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Keith R. Alexandra received a grant of 60.910 Phantom Stock Units on June 27, 2026 under the company’s Deferred Compensation Plan for Directors. These units are credited at $513.03 per unit and are convertible into Common Stock on a 1-for-1 basis.
Following this grant, Alexandra holds a total of 1,331.350 Phantom Stock Units, which will be distributed in shares of Common Stock after his board service ends or upon a change of control.
WEISLER DION J reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Dion J. Weisler received a grant of 73.1 Phantom Stock Units. These derivative units are convertible into Common Stock on a 1-for-1 basis and were credited at a price of $513.03 per unit under the company’s Deferred Compensation Plan for Directors.
Following this award, Weisler holds a total of 2,790.99 Phantom Stock Units. According to the plan, the related shares of Common Stock are distributable after director service ends for any reason or upon a change of control.
THERMO FISHER SCIENTIFIC INC. director Karen S. Lynch received a grant of 60.910 Phantom Stock Units on Common Stock. These units were credited to her deferred compensation account at a price of $513.03 per unit under the Deferred Compensation Plan for Directors.
The Phantom Stock Units convert into Common Stock on a 1-for-1 basis and are distributable as stock when her board service ends for any reason or upon a change of control. Following this grant, her account reflects 352.400 stock units.
THERMO FISHER SCIENTIFIC INC. director Jennifer M. Johnson reported a compensation-related award of phantom stock units. She acquired 60.910 Phantom Stock Units on June 27, 2026, each convertible into one share of Common Stock, bringing her total phantom stock holdings to 722.220 units.
These units were credited at a price of $513.03 per unit under the company’s Deferred Compensation Plan for Directors, where quarterly retainers are deferred into Common Stock units based on the closing stock price at quarter end. The units are distributable as stock after she ceases serving as a director for any reason or upon a change of control.
Fidelity Brokerage Services LLC submitted a Form 144 notice listing proposed sales of common stock on 05/29/2026. The filing lists multiple tranches tied to option grants with quantities of 2,250, 9,138, 11,682, and 22,870 shares shown as to be sold on that date.
The entries reference option grant dates (09/05/2019; 02/25/2020; 02/23/2021; 09/09/2020) and indicate cash as the transaction type. The filing names Fidelity Brokerage Services LLC and lists the exchange as NYSE.
Thermo Fisher Scientific Inc. reported the results of shareholder voting from its May 20, 2026 annual meeting. All nominated directors were elected, each receiving substantially more votes "For" than "Against." For example, Debora L. Spar received 314,426,121 votes for and 311,821 against.
A key outcome was that a non-binding, advisory proposal on the compensation of the company’s named executive officers was not approved, with 99,928,178 votes for and 214,525,673 against. Shareholders also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, by 296,866,709 votes for and 36,064,900 against.
Thermo Fisher Scientific director Dion J. Weisler received a grant of 499 shares of Common Stock, increasing his direct holdings. On the same date, 80.287 shares were withheld at $451.79 per share to satisfy tax obligations related to this award, leaving him with 5,446.384 directly held shares.
Thermo Fisher Scientific director Scott M. Sperling received an award of 499 shares of Common Stock at no cost, classified as a grant or other acquisition. After this compensation grant, he directly holds 69,479 shares of Thermo Fisher Scientific common stock.
Spar Debora L reported acquisition or exercise transactions in this Form 4 filing.
THERMO FISHER SCIENTIFIC INC. director Debora L. Spar reported receiving a grant of 499 shares of Common Stock on May 20, 2026. The award carried a stated price of $0.00 per share, indicating compensation rather than an open-market purchase. After this grant, she directly holds 2,610 shares of Thermo Fisher stock, reflecting a routine equity compensation transaction rather than a market trade.